Redcare Pharmacy

Redcare Pharmacy reports more than 15 million active customers who ordered at least once in the past twelve months, and a reorder rate above 90 percent in the third quarter of 2026. The company still sees significant growth potential, particularly from the introduction of the e-prescription in Germany, where the online share of prescription drugs is currently only around two percent. Compared with countries like Sweden, which have much higher online penetration, the investment story remains attractive over the long term. » More on deraktionaer.de

Redcare Pharmacy benefits from stronger demand for electronic prescriptions and prescription drugs, prompting an upward revision of forecasts. Detailed Q3 figures confirmed analysts' optimism; Berenberg sets a price target of €102, Metzler raised its target to €145 and MPCM/Siering to €125. Siering increased EBIT forecasts but lowered the EPS rating and partly attributes the higher price target to accounting for the convertible bond as debt. The stock showed relative strength in a volatile market and attracted buyers after a pullback. » More on deraktionaer.de

Redcare Pharmacy is benefiting from the e-prescription boom: in the third quarter revenue rose 18% to €847 million, and sales of prescription medicines in Germany climbed 56% to €197 million. Adjusted EBITDA increased 68% to €28.7 million, the adjusted operating margin was 3.4%, and the group swung to an annual profit of €1 million (previous year: -€7 million). Management confirmed the full-year targets and expects 16–18% revenue growth for 2026 with an adjusted EBITDA margin of 2.5–3.0%. After the strong share-price rally, the stock came under short-term pressure from profit-taking. » More on finanzen.net

Redcare Pharmacy increased sales in the third quarter by 18% to €847 million and adjusted EBITDA by 68% to €28.7 million, slightly beating expectations. Despite the positive results, the shares fell about 3.2% to €76.70 in pre-market trading after profit-taking; they had previously risen 57% since mid-September. Analysts rated the figures positively, and Jefferies expects a further upward revision of the full-year outlook. » More on finanzen.net

In the third quarter Redcare Pharmacy’s revenue rose 18% to €847m, while adjusted EBITDA increased 68% to €28.7m, slightly above analyst expectations. The adjusted EBITDA margin was 3.4%; in the DACH region the margin improved year on year to 4.2%. The active customer base grew by 123,000 during the quarter, and management aims to further boost profitability through marketing optimisation and scale effects. Despite the positive numbers, the stock saw profit-taking. » More on deraktionaer.de